How Sibold was paid
$19.2M in total for 2025, as reported in the Summary Compensation Table. Equity awards are valued at grant, not at what they turned out to be worth.
Named executive officers
| Executive | Salary | Bonus | Stock | Options | Incentive | Other | Total |
|---|---|---|---|---|---|---|---|
| Bill SiboldPresident and Chief Executive Officer | $918,531 | — | $12,297,850 | $4,537,146 | $1,438,814 | $14,000 | $19,206,341 |
| Mardi DierExecutive Vice President and Chief Financial Officer | $566,042 | — | $3,561,539 | $1,313,997 | $554,165 | $89,346 | $6,085,089 |
| David Soergel, M.D.Executive Vice President and Chief Medical Officer | $418,182 | $75,000 | $5,911,809 | $2,201,587 | $584,100 | — | $9,190,678 |
| Carole HuntsmanExecutive Vice President and Chief Commercial Officer | $540,313 | — | $3,186,937 | $1,175,671 | $528,976 | $9,839 | $5,441,736 |
| Shannon KelleyExecutive Vice President and Chief Legal Counsel | $535,167 | — | $2,999,636 | $1,106,611 | $523,938 | $14,000 | $5,179,352 |
| Rebecca Taub, M.D.Senior Scientific and Medical Advisor and Former President, Research & Development and Chief Medical Officer | $617,500 | — | $4,124,382 | $1,521,590 | $604,544 | — | $6,868,016 |
What changed and why
- $19.2MCEO total compensation increased to $19,206,341 in 2025 driven by larger stock and option awards.
- $958.4MNet product revenue reached $958.4 million in the first full commercial year.
- 99%Stockholders showed strong support with approximately 99% approval for the say-on-pay proposal.
- More than 36,250 patients were on Rezdiffra therapy as of year-end 2025.
About this page
Figures are automated and can be wrong; check the filing for the exact numbers. Totals follow SEC rules, which value stock and option awards at grant. Read the DEF 14A proxy statement for footnotes and the compensation committee's full reasoning.